A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors

Phase 1

• Conditions: Chronic lymphocytic leukemia, Adrenocortical carcinoma, Breast cancer, Mantle cell lymphoma, Ovarian cancer; MedDRA version: 20.0Level: PTClassification code: 10001388Term: Adrenocortical carcinoma Class: 100000004864; MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104; MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864; MedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864; MedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2024-512019-36-00
• Lead Sponsor: niversitaetsklinikum Wuerzburg AöR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-11
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):